Literature DB >> 20124553

Oxytocin pretreatment of pregnant rat myometrium reduces the efficacy of oxytocin but not of ergonovine maleate or prostaglandin F 2 alpha.

Mrinalini Balki1, Alexandra L Cristian, John Kingdom, Jose C A Carvalho.   

Abstract

Oxytocin receptors (OTRs) in both human and rat myometrial cells are desensitized by exposure to oxytocin, thereby reducing the ability of the cells to respond to the subsequent administration of oxytocin. However, it is unclear if this desensitization phenomenon is confined to oxytocin, or extends to other uterotonic agents such as ergonovine or prostaglandin F(2 alpha) (PGF(2 alpha)). We compared the in vitro contractile responses of myometrial samples from pregnant Wistar rats at 20 to 22 days of gestation. Longitudinal myometrial strips isolated from each animal were pretreated with either oxytocin 10(-8) mol/L (experimental groups) or physiological salt solution (control groups) for 1 hour in organ bath chambers, and then subjected to a dose-response study with oxytocin (n = 28), ergonovine (n = 16), or PGF(2 alpha) (n = 16), with cumulative increases in the organ bath concentrations from 10(- 10) to 10(-5) mol/L. The amplitude and frequency of the contractions during the dose-response period were analyzed using mixed linear modeling and compared between the groups. Oxytocin pretreatment significantly suppressed the mean amplitude of the myometrial contractions as compared to the controls when the strips were further subjected to oxytocin (1.02 vs 1.74 g; P < .0001), but not with further exposure to ergonovine (0.77 vs. 0.58 g; P = .11) or PGF(2 alpha) (0.83 vs 0.94 g; P = .4). However, oxytocin produced superior contractions in the control and oxytocin-pretreated myometrium compared to either ergonovine or PGF(2 alpha). Our study shows that the uterotonic effects of ergonovine and PGF(2 alpha) are not affected by the phenomenon of oxytocin desensitization in pregnant rat myometrium. However, oxytocin, despite the phenomenon of desensitization, provides superior uterine contractions when compared to ergonovine or PGF(2 alpha).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20124553     DOI: 10.1177/1933719109351934

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  6 in total

1.  The Oxytocin Product Correlates with Total Oxytocin Received during Labor: A Research Methods Study.

Authors:  Chad A Grotegut; Lauren L Lewis; Tracy A Manuck; Terrence K Allen; Andra H James; Aurelien Seco; Catherine Deneux-Tharaux
Journal:  Am J Perinatol       Date:  2017-08-14       Impact factor: 1.862

2.  Second-line uterotonics and the risk of hemorrhage-related morbidity.

Authors:  Alexander J Butwick; Brendan Carvalho; Yair J Blumenfeld; Yasser Y El-Sayed; Lorene M Nelson; Brian T Bateman
Journal:  Am J Obstet Gynecol       Date:  2015-01-09       Impact factor: 8.661

3.  β-Arrestin mediates oxytocin receptor signaling, which regulates uterine contractility and cellular migration.

Authors:  Chad A Grotegut; Liping Feng; Lan Mao; R Phillips Heine; Amy P Murtha; Howard A Rockman
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-12-07       Impact factor: 4.310

Review 4.  What Do Current Information and Evidence Suggest to Us for Oxytocin Use During Caesarean Section?

Authors:  Berrin Günaydın; Ayça Taş Tuna
Journal:  Turk J Anaesthesiol Reanim       Date:  2015-02-05

5.  Enhanced Uterine Contractility and Stillbirth in Mice Lacking G Protein-Coupled Receptor Kinase 6 (GRK6): Implications for Oxytocin Receptor Desensitization.

Authors:  Chad A Grotegut; Lan Mao; Stephanie L Pierce; Geeta K Swamy; R Phillips Heine; Amy P Murtha
Journal:  Mol Endocrinol       Date:  2016-02-17

Review 6.  Lack of controlled studies investigating the risk of postpartum haemorrhage in cesarean delivery after prior use of oxytocin: a scoping review.

Authors:  Karin Bischoff; Monika Nothacker; Cornelius Lehane; Britta Lang; Joerg Meerpohl; Christine Schmucker
Journal:  BMC Pregnancy Childbirth       Date:  2017-11-29       Impact factor: 3.007

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.